

Radius Health, Inc. Investor Relations Department 950 Winter St, North ?Building 1st Floor North Building 1st Floo Waltham, MA 02451 United States

Visit IR website ☐ Sign-up for Email alerts ☐ ☐

NASDAQ: RDUS	
Last Trade:	29.01
Trade Time:	3:16 PM ET May 22, 2018
Change:	0.00 (0.000%)
Day Range	28.25 - 29.68
52-Week Range	24.66 - 49.16
Volume	771,961

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Company Profile**

Radius is a sciencedriven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS® (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch f... (more)

## **Stock Performance**



## Press Releases [View all]

May 11, 2018

Radius Health to Present at the Bank of America Merrill Lynch 2018 Annual Healthcare Conference

May 10, 2018

Radius Health Reports First Quarter 2018
Financial and Operating Results and
Provides Business Update

Apr 24, 2018

Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10, 2018

Mar 30, 2018

Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis

Mar 22, 2018

Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC

## Financials [View all]

First Quarter Financial Results

Mar 1, 2018

Annual Report (10-K)

Apr 20, 2018

Proxy Statement (DEF 14A)

May 10, 2018

Quarterly Report (10-Q)

Nov 2, 2017

Quarterly Report (10-Q)

Aug 4, 2017

Quarterly Report (10-Q)